معرفی
Dr. Onima Chowdhury is a Clinician Scientist and Consultant Haematologist at Oxford University Hospitals, specializing in myeloid malignancies. She serves as a clinical lead in the diagnostics laboratory and conducts research applying single cell sequencing technologies to improve diagnosis and patient care for blood cancer patients.
Her educational background includes:
- Medical training at the University of Cambridge
- Further medical training at the University of Oxford
- Specialist haematology training at UCL and Oxford
- DPhil from Oxford University in 2014, focusing on stem cells in myeloid malignancies under Professor Sten Eirik Jacobsen
Dr. Chowdhury's research focuses on applying cutting-edge single cell sequencing technologies to improve diagnosis and treatment of myeloid malignancies. Her work examines mutational landscapes in myelofibrosis, stem cell characterization in blood cancers, and using genomic approaches for early diagnosis and treatment response prediction. She investigates how genetic mutations affect disease progression and therapy outcomes.
Her publication record demonstrates consistent focus on myeloid malignancies, particularly examining genetic mutations, stem cell biology, and targeted therapies. Key research areas include spliceosome mutations in myelofibrosis, JAK2 mutations, and the role of cancer stem cells in disease propagation, with emphasis on translating genomic findings to clinical applications.
Dr. Chowdhury has received notable scientific recognition:
- NIHR Academic Clinical Lectureship for investigating mutational landscape in myelofibrosis
- MRC Clinical Academic Research Partnership Award (2020) for single cell sequencing applications in early diagnosis
As both a clinician and researcher, Dr. Chowdhury bridges patient care with cutting-edge genomic technologies. Her current MRC-funded research focuses on clinical applications of single cell sequencing for early diagnosis and response prediction in myeloid malignancies, conducted in collaboration with Professor Mead. She leads diagnostic laboratory efforts focused on implementing novel genomic technologies to improve patient outcomes in myeloid malignancy care.
She maintains active clinical practice while advancing research that directly impacts diagnostic approaches and treatment strategies for patients with blood cancers.
